Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation

Brain, Behavior, and Immunity

Volumn 59, Issue , 2017, Pages 10-20

  Shamran, Haidar ^a   Singh, Narendra P ^a   Zumbrun, Elizabeth E ^a   Murphy, Angela ^a   Taub, Dennis D ^b   Mishra, Manoj K ^c   Price, Robert L ^a   Chatterjee, Saurabh ^d   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a   Singh, Udai P ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ALABAMA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Colitis; FAAH; Inflammation; Inflammatory bowel disease; MicroRNAs

Indexed keywords

ANANDAMIDE; DEXTRAN SULFATE; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; GAMMA INTERFERON; GLYCOPROTEIN P 15095; SMAD2 PROTEIN; TRANSCRIPTION FACTOR FKHR; AMIDASE; ANTIINFLAMMATORY AGENT; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CROHN DISEASE; DENDRITIC CELL; DISEASE COURSE; DOWN REGULATION; ENTERITIS; ENZYME INHIBITION; EXPERIMENTAL COLITIS; FLOW CYTOMETRY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LAMINA PROPRIA; MESENTERY LYMPH NODE; MICROARRAY ANALYSIS; MORBIDITY; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PEYER PATCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BODY WEIGHT LOSS; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; COLON; DRUG EFFECT; FEMALE; INTESTINE MUCOSA; MACROPHAGE; PATHOLOGY; T LYMPHOCYTE;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; DEXTRAN SULFATE; ENZYME INHIBITORS; FEMALE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MACROPHAGES; MICE; MICE, INBRED C57BL; RNA, MESSENGER; T-LYMPHOCYTES; WEIGHT LOSS;

EID: 84977491345     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.06.008     Document Type: Article

References (53)

1. Altamemi, I., Murphy, E.A., Catroppo, J.F., Zumbrun, E.E., Zhang, J., McClellan, J.L., Singh, U.P., Nagarkatti, P.S., Nagarkatti, M., Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice. J. Pharmacol. Exp. Ther. 350 (2014), 99–109.
2. Ambros, V., The functions of animal microRNAs. Nature 431 (2004), 350–355.
3. Boiardi, L., Macchioni, P., Meliconi, R., Pulsatelli, L., Facchini, A., Salvarani, C., Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin. Exp. Rheumatol. 17 (1999), 419–425.
4. Braegger, C.P., MacDonald, T.T., Immune mechanisms in chronic inflammatory bowel disease. Ann. Allergy 72 (1994), 135–141.
5. Casini-Raggi, V., Kam, L., Chong, Y.J., Fiocchi, C., Pizarro, T.T., Cominelli, F., Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154 (1995), 2434–2440.
6. Cluny, N.L., Keenan, C.M., Duncan, M., Fox, A., Lutz, B., Sharkey, K.A., Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J. Pharmacol. Exp. Ther. 334 (2010), 973–980.
7. Coskun, M., Bjerrum, J.T., Seidelin, J.B., Nielsen, O.H., MicroRNAs in inflammatory bowel disease–pathogenesis, diagnostics and therapeutics. World J. Gastroenterol. 18 (2012), 4629–4634.
8. D'Argenio, G., Valenti, M., Scaglione, G., Cosenza, V., Sorrentini, I., Di Marzo, V., Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20 (2006), 568–570.
9. Dohi, T., Fujihashi, K., Kiyono, H., Elson, C.O., McGhee, J.R., Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 119 (2000), 724–733.
10. Elson, C.O., Beagley, K.W., Sharmanov, A.T., Fujihashi, K., Kiyono, H., Tennyson, G.S., Cong, Y., Black, C.A., Ridwan, B.W., McGhee, J.R., Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J. Immunol. 157 (1996), 2174–2185.
11. Engel, M.A., Kellermann, C.A., Burnat, G., Hahn, E.G., Rau, T., Konturek, P.C., Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. J. Physiol. Pharmacol. 61 (2010), 89–97.
12. Esteller, M., Non-coding RNAs in human disease. Nat. Rev. Genet. 12 (2011), 861–874.
13. Feng, X., Wang, H., Ye, S., Guan, J., Tan, W., Cheng, S., Wei, G., Wu, W., Wu, F., Zhou, Y., Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PLoS ONE, 7, 2012, e52782.
14. Grose, R.H., Howarth, G.S., Xian, C.J., Hohmann, A.W., Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse. J. Gastroenterol. Hepatol. 16 (2001), 1228–1234.
15. Guo, H., Ingolia, N.T., Weissman, J.S., Bartel, D.P., Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466 (2010), 835–840.
16. Holtkamp, W., Stollberg, T., Reis, H.E., Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J. Clin. Gastroenterol. 20 (1995), 123–126.
17. Huang, Z., Shi, T., Zhou, Q., Shi, S., Zhao, R., Shi, H., Dong, L., Zhang, C., Zeng, K., Chen, J., Zhang, J., MiR-141 Regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut 63 (2014), 1247–1257.
18. Ito, Y., Daitoku, H., Fukamizu, A., Foxo1 increases pro-inflammatory gene expression by inducing C/EBPbeta in TNF-alpha-treated adipocytes. Biochem. Biophys. Res. Commun. 378 (2009), 290–295.
19. Izzo, A.A., Camilleri, M., Cannabinoids in intestinal inflammation and cancer. Pharmacol. Res. 60 (2009), 117–125.
20. Izzo, A.A., Sharkey, K.A., Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 126 (2010), 21–38.
21. Keates, S., Keates, A.C., Mizoguchi, E., Bhan, A., Kelly, C.P., Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am. J. Physiol. 273 (1997), G75–G82.
22. Kimball, E.S., Schneider, C.R., Wallace, N.H., Hornby, P.J., Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am. J. Physiol. – Gastrointestinal Liver Physiol. 291 (2006), G364–G371.
23. Malhotra, N., Robertson, E., Kang, J., SMAD2 is essential for TGF beta-mediated Th17 cell generation. J. Biol. Chem. 285 (2010), 29044–29048.
24. Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B.F., Ferri, G.L., Sibaev, A., Storr, M., Lutz, B., The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113 (2004), 1202–1209.
25. Mayer, E.A., Collins, S.M., Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 122 (2002), 2032–2048.
26. McCormack, G., Moriarty, D., O'Donoghue, D.P., McCormick, P.A., Sheahan, K., Baird, A.W., Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflammation Res. 50 (2001), 491–495.
27. Natsui, M., Kawasaki, K., Takizawa, H., Hayashi, S.I., Matsuda, Y., Sugimura, K., Seki, K., Narisawa, R., Sendo, F., Asakura, H., Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats. J. Gastroenterol. Hepatol. 12 (1997), 801–808.
28. Ogawa, A., Andoh, A., Araki, Y., Bamba, T., Fujiyama, Y., Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110 (2004), 55–62.
29. Podolsky, D.K., Inflammatory bowel disease. N. Engl. J. Med. 347 (2002), 417–429.
30. Ranjha, R., Aggarwal, S., Bopanna, S., Ahuja, V., Paul, J., Site-specific MicroRNA expression may lead to different subtypes in ulcerative colitis. PLoS ONE, 10, 2015, e0142869.
31. Reimund, J.M., Wittersheim, C., Dumont, S., Muller, C.D., Kenney, J.S., Baumann, R., Poindron, P., Duclos, B., Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 39 (1996), 684–689.
32. Salaga, M., Sobczak, M., Fichna, J., Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract. Eur. J. Pharm. Sci. 52 (2014), 173–179.
33. Sartor, R.B., Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3 (2006), 390–407.
34. Sartor, R.B., Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008), 577–594.
35. -/- mice precedes expression in the colon. J. Immunol. 18 (2011), 5834–5841.
36. -/- mice reconstituted with CD4+CD45RBhigh T cells. Eur. J. Immunol. 31 (2001), 1465–1474.
37. Singh, U.P., Murphy, A.E., Enos, R.T., Shamran, H.A., Singh, N.P., Guan, H., Hegde, V.L., Fan, D., Price, R.L., Taub, D.D., Mishra, M.K., Nagarkatti, M., Nagarkatti, P.S., MiR-155 deficiency protects mice from experimental colitis by reducing Th1/Th17 responses. Immunology 143 (2014), 479–489.
38. Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M., Nagarkatti, P.S., Resveratrol (trans-3,5,4’-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J. Pharmacol. Exp. Ther. 332 (2010), 829–839.
39. -/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacol. 258 (2012), 256–267.
40. + leukocytes during Mycobacteria-enhanced colitis. BMC Immunol., 9, 2008, 25.
41. -/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J. Interferon Cytokine Res. 28 (2008), 31–43.
42. -/-) mice. J. Immunol. 171 (2003), 1401–1406.
43. Stella, N., Schweitzer, P., Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997), 773–778.
44. Storr, M.A., Keenan, C.M., Emmerdinger, D., Zhang, H., Yuce, B., Sibaev, A., Massa, F., Buckley, N.E., Lutz, B., Goke, B., Brand, S., Patel, K.D., Sharkey, K.A., Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. 86 (2008), 925–936.
45. Storr, M.A., Keenan, C.M., Zhang, H., Patel, K.D., Makriyannis, A., Sharkey, K.A., Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm. Bowel Dis. 15 (2009), 1678–1685.
46. Strober, W., Fuss, I., Mannon, P., The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117 (2007), 514–521.
47. Strober, W., Fuss, I.J., Blumberg, R.S., The immunology of mucosal models of inflammation. Ann. Rev. Immunol. 20 (2002), 495–549.
48. Strober, W., James, S.P., The immunologic basis of inflammatory bowel disease. J. Clin. Immunol. 6 (1986), 415–432.
49. Vila, L.M., Molina, M.J., Mayor, A.M., Cruz, J.J., Rios-Olivares, E., Rios, Z., Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin. Rheumatol. 26 (2007), 718–722.
50. Wu, F., Guo, N.J., Tian, H., Marohn, M., Gearhart, S., Bayless, T.M., Brant, S.R., Kwon, J.H., Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 17 (2011), 241–250.
51. Wu, F., Zikusoka, M., Trindade, A., Dassopoulos, T., Harris, M.L., Bayless, T.M., Brant, S.R., Chakravarti, S., Kwon, J.H., MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology, 135(1624–1635), 2008, e1624.
52. Yin, H., Hu, M., Zhang, R., Shen, Z., Flatow, L., You, M., MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J. Biol. Chem. 287 (2012), 9817–9826.
53. Zidar, N., Bostjancic, E., Jerala, M., Kojc, N., Drobne, D., Stabuc, B., Glavac, D., Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases – hallmark of epithelial-mesenchymal transition. J. Cell Mol Med., 2016.